On January 6, 2025, the U.S. Food and Drug Administration (FDA) released draft guidance titled Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and ...
Asianet Newsable on MSN
ELVN stock on track for best week since March following FDA-aligned path for cancer drug development
As of March 2026, ELVN-001 produced meaningful responses in heavily pretreated patients, many of whom had already tried ...
June 3 (Reuters) - The U.S. FDA's Center for Drug Evaluation and Research said on Wednesday it has accepted a letter of ...
Belite Bio, Inc (NASDAQ: BLTE) ('Belite Bio®” or the 'Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have ...
FDA's draft guidance shows gene therapy developers how to use prior knowledge and platform data to accelerate regulatory ...
Critical Path Institute® (C-Path) will host its 2026 Global Impact Conference (CGIC) this September at the Washington ...
In a much-anticipated draft guidance issued on Thursday, the US Food and Drug Administration (FDA) said that unlike smallpox therapeutics, treatments for mpox cannot be developed under the Animal Rule ...
Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer ...
The FDA has proposed new policies to speed up the development and lower the cost of biosimilar agents for cancer and other serious illnesses. These policies include “major updates to simplify ...
Sorensen recently reintroduced the bipartisan STOP GAMES Act, legislation aimed at preventing what he describes as "sham" ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results